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Methylmalonic acidemia (MMA) is an organic acidemia 
caused by deficient activity of the mitochondrial enzyme 
methylmalonyl-CoA  mutase  (MUT).  This  disorder  is 
associated with lethal metabolic instability and carries a 
poor prognosis for long-term survival. A murine model 
of MMA that replicates a severe clinical phenotype was 
used  to  examine  the  efficacy  of  recombinant  adeno-
associated  virus  (rAAV)  serotype  8  gene  therapy  as  a 
treatment for MMA. Lifespan extension, body weight, 
circulating metabolites, transgene expression, and whole 
animal propionate oxidation were examined as outcome 
parameters  after  gene  therapy.  One-hundred  percent 
of the untreated Mut−/− mice (n = 58) died by day of 
life (DOL) 72, whereas >95% of the adeno-  associated 
virus–treated Mut−/− mice (n = 27) have survived for ≥1 
year. Despite a gradual loss of transgene expression and 
elevated circulating metabolites in the treated Mut−/− 
mice, the animals are indistinguishable from unaffected 
control  littermates  in  size  and  activity  levels.  These 
experiments  provide  the  first  definitive  evidence  that 
gene therapy will have clinical utility in the treatment of 
MMA and support the development of gene therapy for 
other organic acidemias.
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27 October 2009. doi:10.1038/mt.2009.247
IntroductIon
Methylmalonic  acidemia  (MMA)  is  a  severe  autosomal  reces-
sive inborn error of intermediary metabolism characterized by 
intermittent metabolic instability, multiorgan pathology, growth 
retardation, and a poor prognosis for long-term survival.1–6 The 
disorder exhibits genetic heterogeneity and can be caused by defi-
cient enzymatic activity of methylmalonyl-CoA mutase (MUT) 
or defective intracellular transport, processing, and metabolism 
of cobalamin.7 MUT is an important mitochondrial enzyme in 
propionyl-CoA metabolism and converts l-methylmalonyl-CoA 
into succinyl-CoA, a Krebs cycle intermediate. A block at this 
enzymatic step results in elevated plasma levels of   methylmalonic 
acid as well the accumulation of other propionyl-CoA-derived 
metabolites such as 2-methylcitrate.8 The etiology of the many 
medical problems that patients with MMA suffer is not well under-
stood. However, the wide spectrum of severity that can be seen in 
patients who harbor missense mutations suggests that restoring a 
very low level of enzyme activity would provide substantial clini-
cal benefit.
Currently, the main treatment for affected patients is dietary 
restriction  of  propiogenic  amino  acids  to  reduce  circulating 
metabolites. Liver9–15 and/or combined liver/kidney16,17 transplan-
tation has been performed in a limited fashion in an attempt to 
improve metabolic stability through the provision of organ-spe-
cific enzymatic activity. Although this approach has been effective, 
and even curative, for other metabolic disorders,18 the clinical util-
ity of solid organ transplantation as a standard treatment for MMA 
is unclear given the small number of patients that have undergone 
the procedure.14,15,19 The need for new and widely available thera-
pies for MMA is underscored by a recent multicenter European 
long-term patient study, which described an overall 46% (n = 52) 
mortality for patients with MMA resulting from MUT deficiency 
by 30 years of age.6
We have previously developed a murine model of MMA 
that  replicates  the  severest  clinical  phenotype  of  MMA  seen 
in patients.20 Affected animals display a 100–200-fold increase 
in plasma methylmalonic acid concentrations and most per-
ish within the first few days of life.20,21 Recently, we reported 
that  direct  hepatic,  but  not  intramuscular,  injection  of  an 
adenovirus that expressed the Mut gene under the control of 
a  cytomegalovirus  promoter  could  only  partially  rescue  the 
Mut−/− mice.22 A liver-directed approach was initially selected 
because the hepatocytes of Mut−/− mice and MMA patients 
manifest morphological changes and display a severe secondary 
electron transport chain defect that is likely contributory to the 
pathology of the disease.21 Additionally, we had demonstrated 
that robust correction of human MUT−/− hepatocytes was fea-
sible with this vector.23 However, in the surviving adenoviral-
treated Mut−/− mice, the Mut levels steadily declined, and most 
animals died between 1 and 3 months after treatment. These 
results suggested that persistent expression would be needed to 
provide long-term amelioration of the lethal phenotype in this 
murine model of MMA.
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Recombinant  adeno-associated  viruses  (rAAVs)  have  been 
successfully used as gene delivery vehicles in numerous animal 
models of human disease and have yielded long-term transgene 
expression without vector-related toxicity. Furthermore, clinical 
trials using rAAV have involved hundreds of subjects, supporting 
the safety of these vectors for use in humans.24 Over 100 differ-
ent natural AAV serotypes have been isolated from a variety of 
species and some display striking tissue tropism.25 Several stud-
ies have demonstrated that rAAV serotype 8 (rAAV8) vectors can 
transduce mouse hepatocytes with high efficiency when delivered 
via the portal vein or intraperitoneal injection in the neonatal 
period.26–28  Similarly,  rAAV8  vectors  can  efficiently  transduce 
skeletal muscle,29,30 a tissue that makes a significant contribution 
to the circulating metabolite pool in patients with MMA.20
In this report, we describe the therapeutic efficacy of a rAAV 
vector as a new gene therapy treatment for MMA and apply a novel 
stable isotope metabolic method to monitor the function of Mut 
after gene therapy. The treated Mut−/− mice have reduced circu-
lating metabolites, are phenotypically indistinguishable from their 
unaffected Mut+/− mice littermates and show sustained enzymatic 
activity 1 year after treatment with the rAAV8 vector. Our results 
provide the first evidence that systemic gene delivery using rAAV 
should be useful as a treatment for patients with MMA and other 
organic acidemias, disorders that currently lack definitive therapy. 
This gene delivery platform and metabolic monitoring technique 
should be immediately translatable to a human gene therapy trial 
for MMA.
results
Gene therapy rescues the lethal Mut−/− phenotype
Mut−/− newborn mice received a direct hepatic injection with 
either 1 or 2 × 1011 vector genome copies (GCs) of rAAV8-mMut. 
All Mut−/− mice (n = 27) injected in the neonatal period with 
rAAV8-mMut survived until day of life (DOL) 90 (Figure 1). 
A single Mut−/− mouse from the rAAV8-mMut 1 × 1011 GC group 
perished at DOL 92 following a blood collecting procedure; a full 
necropsy was performed, and no abnormalities were observed. 
Ninety-six  percent  (26/27)  of  the  Mut−/−  mice  treated  with 
rAAV8-mMut have survived beyond a year. In contrast, 100% of 
the untreated mutants (n = 58) perished by DOL 72, with >90% of 
this group dying by DOL 24. In another control group, newborn 
Mut−/− mice (n = 18) received a direct hepatic injection with 
either 1 or 2 × 1011 GC of rAAV8 containing green fluorescent 
protein (GFP) complementary DNA driven by the same chicken 
β-actin promoter/enhancer (Figure 1). None of the rAAV8-GFP-
treated Mut−/− mice survived beyond DOL 3. Untreated Mut−/− 
mice and rAAV8-GFP-treated Mut−/− animals were found dead 
or cannibalized; the exact causes of death were undetermined. 
To determine whether direct hepatic injection was necessary to 
rescue Mut−/− mice, newborn Mut−/− mice (n = 4) received an 
intraperitoneal injection of 3 × 1011 GC rAAV8-mMut. Three out 
of the four (75%) of these mice survived and are still alive at DOL 
120 (Figure 1). Other than mild hepatomegaly, the Mut−/− mice 
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Figure  1  rescue  of  Mut−/−  mice.  Survival  in  days  between  the 
untreated Mut−/− mice (n = 58), intrahepatic-injected rAAV8-GFP 1 or 
2 × 1011 GC Mut−/− mice (n = 18), intrahepatic-injected rAAV8-mMut 
1 × 1011 GC (n = 10) or 2 × 1011 GC (n = 17) Mut−/− mice, and i.p. 
rAAV8-mMut 3 × 1011 GC injected (n = 4) Mut−/− mice. All three groups 
of rAAV8-mMut-treated Mut−/− mice exhibited a significant improve-
ment in survival relative to untreated and rAAV8-GFP-treated Mut−/− 
mice. The intrahepatic-injected rAAV8-mMut-treated Mut−/− mice show 
significantly improved survival at 24, 60, and 100 days and beyond 
compared to the untreated and rAAV8-GFP-treated Mut−/− mice (*P < 
10−22 for rAAV8-mMut 1 × 1011 GC and **P < 10−22 for rAAV8-mMut 
2 × 1011 GC at the 100-day time point). GC, genome copy; GFP, green 
  fluorescent protein; i.p., intraperitoneal.
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Figure  2  Growth  and  phenotypic  correction  after  rAAV8-mMut 
gene therapy. (a) An untreated Mut−/− mouse (left) compared to a 
Mut+/− littermate at day of life 55 to illustrate the relative difference in 
size and appearance. The Mut−/− mouse is severely growth retarded and 
has achieved only 40% of the Mut+/− littermate weight. Shortly after this 
photo was taken, the Mut−/− mouse became lethargic and perished. 
(b) A Mut−/− mouse (left, neck flexed) that received a single intrahe-
patic injection of rAAV8-mMut 2 × 1011 GC aside a Mut+/− littermate 
(right, neck extended) at day of life 120. The treated Mut−/− animal 
is similar in size to a control Mut+/− littermate. (c) Growth correction 
between  untreated  Mut−/−  mice,  intrahepatic  rAAV8-mMut-treated 
Mut−/− mice, and untreated age-, diet-, and gender-matched Mut+/− 
littermates. The graph depicts the percent weight at day of life 24 and 
60 of Mut+/− diet- and gender-matched littermates (n = 25, 25) com-
pared to untreated Mut−/− mice (n = 6, 3) or Mut−/− mice treated via 
an intrahepatic injection of rAAV8-mMut 1 × 1011 GC (n = 10, 10) or 
rAAV8-mMut 2 × 1011 GC (n = 17, 17) at birth. The rAAV8-mMut-treated 
Mut−/− mice at both doses showed significant growth improvement 
compared to the untreated Mut−/− mice (*P < 10−6 for day 24, **P < 0.01 
for day 60). Error bars represent plus and minus one standard deviation. 
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(n = 4) treated by rAAV8-mMut gene therapy and sacrificed for 
tissue harvesting on DOL 90 or at 1 year had no gross pathologic 
changes noted on dissection.
correction of growth retardation following gene 
therapy
Mut−/−  mice  were  indistinguishable  from  their  Mut+/−  lit-
termates at birth, but those rare mutants that escaped neonatal 
lethality were grossly abnormal. The small number of untreated 
Mut−/− mice that survived to DOL 24 (6/58) and 60 (3/58) were 
severely growth retarded, weighing <40% of sex-matched Mut+/− 
littermates (Figure 2a). Mut−/− mice treated with an intrahepatic 
injection of either 1 or 2 × 1011 GC of rAAV8-mMut were grossly 
indistinguishable  in  size  and  behavior  compared  to  controls 
(Figure 2b) and achieved body weights that were similar to their 
Mut+/− sex-matched littermates on DOL 24 and 60 (Figure 2c).
expression of Mut after treatment with rAAV8-mMut
Mut expression in liver and muscle samples from treated Mut−/− 
mice at DOL 90 and 1 year of life was analyzed using quantitative 
PCR (qPCR) to measure mRNA levels and by western blotting to 
examine protein content. The Mut−/− mice at DOL 90 injected 
with either 1 or 2 × 1011 GC of rAAV8 expressed 38 and 72% of 
the endogenous Mut mRNA levels found in the liver of untreated 
Mut+/− animals (Figure 3a), whereas the level of Mut mRNA in 
the lower limb skeletal muscle of treated animals exceeded the 
endogenous Mut transcript levels measured to control heterozy-
gotes (Figure 3a). Even greater expression was noted in the hearts 
of  the  treated  Mut−/−  mice  compared  to  untreated  Mut+/− 
mice,  consistent  with  previous  observations  of  highly  efficient 
transduction of cardiac and skeletal myocytes by rAAV8 vectors.30 
Mut mRNA was variably detected in whole brain extracts and not 
detected in the kidney or spleen. Western blotting showed Mut 
protein in both the liver and the skeletal muscle of the treated 
Mut−/− mice at levels that paralleled those observed in the qPCR 
experiments on DOL 90 (Figure 3b). Mice studied at longer times 
showed persistent expression of the Mut transgene. The levels of 
Mut mRNA in the liver and skeletal muscle of treated Mut−/− 
mice 1 year after injection diminished but was still readily detect-
able by qPCR (Figure 3a), but not by western analysis.
Gene therapy restores Mut function and activity
Several  parameters  reflective  of  Mut  enzymatic  function  were 
examined in the treated Mut−/− mice. Circulating metabolites were 
measured and taken to reflect whole-body Mut enzymatic activity 
because all the mice ingested a precursor unrestricted diet. The 
plasma methylmalonic acid concentrations in the treated Mut−/− 
mice were significantly lower than in untreated Mut−/− mice at 
both time points measured (Figure 4a). The untreated Mut−/− 
mice  had  mean  plasma  methylmalonic  acid  concentrations  of 
1,342 and 1,120 µmol/l on days 24 and 60. No untreated Mut−/− 
mice survived beyond day 72; therefore, plasma methylmalonic 
acid levels after day 60 from this group could not be obtained. 
Both the 1 and 2 × 1011 GC groups of treated Mut−/− mice had 
mean  plasma  methylmalonic  acid  concentrations  between  440 
and 540 µmol/l at the day 24 and 60 time points. Metabolites in 
these two groups of treated Mut−/− mice were also measured at 90, 
120, 180, and 360 days with the mean methylmalonic acid levels 
at these time points ranging from 365 to 596 µmol/l (Figure 4a). 
As observed in humans with MMA whom have received liver or 
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combined liver–kidney transplants, plasma metabolites were not 
normalized13,16,17  and  remained  50–100-fold  increased  over  the 
level seen in unaffected Mut+/− mice (5–10 µmol/l).
To examine whether the long-term survival and ameliorated 
metabolite  levels  observed  in  the  treated  Mut−/−  mice  corre-
sponded with increased whole-body enzyme activity, we developed 
a novel in vivo propionate oxidation assay. Mut−/− mice at 1 year 
after treatment were injected with 1-13C-sodium propionate and 
the subsequent metabolism of this tracer through the Mut reac-
tion, into the Krebs cycle, with eventual oxidation into 13CO2 was 
determined. As can be seen in Figure 4b, Mut+/− mice metabo-
lize ~70% of 1-13C-propionate into 13CO2 in 25 minutes. Untreated 
Mut−/− mice convert ~10% of the dose, with very flat enrich-
ment kinetics. At 1 year of age, the treated Mut−/− mice show a 
markedly increased capacity to oxidize 1-13C-propionate and on 
average, can convert ~40% of the injected dose into 13CO2.
rAAV8-mMut rescues postneonatal Mut−/− mice
As an extension of rAAV8-mMut gene therapy beyond the imme-
diate  neonatal  period,  three  rare  untreated  Mut−/−  mice  that 
  survived  until  DOL  20  received  a  single  intraperitoneal  injec-
tion of 3 × 1011 GC of rAAV8-mMut. At the time of injection, 
the animals were hypoactive, runted (Figure 5a) and showed an 
impaired ability to produce 13CO2 from 1-13C-propionate. When 
studied 10 days after receiving the rAAV8-mMut, the mice had 
an improved clinical appearance (Figure 5a), fully restored propi-
onate oxidation (Figure 5b) and displayed a tenfold reduction in 
plasma methylmalonic acid concentrations (Figure 5c).
dIscussIon
The experiments undertaken in the present report were designed 
to test the efficacy of rAAV-mediated gene therapy in a murine 
model of MMA, a prototypical organic acidemia. Our earlier stud-
ies in Mut−/− mice22 and the demonstration that liver transplanta-
tion appears beneficial for a subset of MMA patients15 led to the 
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Figure  4  Metabolic  improvements  after  rAAV8-mMut  treatment. 
(a) Plasma methylmalonic acid levels (µmol/l) were measured at time 
points of 24, 90, 120, 180, and 360 days after birth in the rAAV8-mMut-
treated Mut−/− mice as an indication of Mut activity. Three groups are 
presented: untreated Mut−/− mice, Mut−/− mice treated with 1 × 1011 
GC rAAV8-mMut, and Mut−/− mice treated with 2 × 1011 GC rAAV8-
mMut. Untreated and treated Mut+/− mice have plasma methylmalonic 
acid levels between 5 and 10 µmol/l, and are not depicted in this graph. 
The numbers in each group are presented in the graph. Error bars rep-
resent plus and minus one standard deviation. The rAAV8-mMut-treated 
mutant mice show a significant reduction in plasma methylmalonic acid 
levels compared to the untreated Mut−/− mice at all time points (*P < 
0.001 on day 24, **P < 0.01 on day 90). (b) 1-13C-propionate oxidation 
1 year after rAAV8-mMut treatment. Two hundred micrograms of 1-13C-
sodium propionate was injected intraperitoneally into Mut+/− (n = 8), 
1 × 1011 GC rAAV8-mMut-treated Mut−/− (n = 3), or untreated Mut−/− 
(n = 6) mice. 13C enrichment in expired CO2 was measured and used 
to  determine  the  percent  of  the  administered  1-13C-propionate  dose 
that was oxidized. Error bars surround the 95% confidence intervals. 
The rAAV8-mMut-treated Mut−/− mice show a significant increase in the 
ability to oxidize 1-13C-propionate compared to the untreated Mut−/− 
mice at 25 minutes (*P < 0.01). GC, genome copy.
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Figure 5  rAAV8-mMut treatment in 20-day-old Mut−/− mice. (a) A 
Mut−/− mouse was treated on day of life (DOL) 20 with 3 × 1011 GC 
rAAV8-mMut delivered intraperitoneally (i.p.), and serial weights were 
measured  in  parallel  with  a  control  Mut+/−  littermate.  The  treated 
Mut−/− mouse achieved the control weight 40 days after treatment. 
(b) Two hundred micrograms of 1-13C-propionate was injected i.p. into 
Mut−/− mice (labeled Mut−/− pre-rAAV, n = 3) or control Mut+/− litter-
mates (labeled Mut+/−, n = 3) on DOL 20 prior to receiving 3 × 1011 GC 
rAAV8-mMut. The study was repeated 10 days after the viral injection and 
propionate oxidation at 20 minutes in the treated Mut−/− mice (labeled 
Mut−/− post-rAAV, n = 3) achieved levels that were significantly greater 
than the untreated mutants (*P < 0.01) and equivalent to the controls. 
Error bars surround the standard deviation. (c) Plasma methylmalonic 
acid levels in response to rAAV8 treatment on DOL 20 in Mut−/− mice 
(n = 3). Before (pre-rAAV; mean 1,011 µmol/l) was significantly more 
than after (post-rAAV; mean 118 µmol/l). *P < 0.05. Error bars surround 
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selection of adeno-associated virus serotype 8 as a gene delivery 
vector.  The  observed  results  are  striking:  a  single  intrahepatic 
injection of rAAV8-mMut delivered in the neonatal period was 
sufficient to uniformly rescue treated Mut−/− mice from certain 
death for over a year. The effects of gene therapy extended beyond 
immediate mortality and allowed the treated Mut−/− mice to gain 
weight, thrive, and reproduce. Limited pathological investigations 
have been performed on the treated mutants at older times and will 
be the subject of future studies, particularly to examine whether 
renal, hepatic, central nervous system, or pancreatic changes are 
present and if they have functional consequences for the treated 
mice. The treated Mut−/− animals were also able to tolerate a 
  liberalized  diet  in  the  face  of  elevated  circulating  metabolites, 
which were greatly diminished compared to the untreated Mut−/− 
group, but still significantly increased compared to heterozygous 
controls. The Mut−/− mice, both treated and untreated, did not 
receive a precursor-restricted diet, commonly employed to treat 
patients31 that likely would have further decreased methylmalonic 
acid levels in the treated animals. Complete restoration of plasma 
metabolites to normal in the treated mice was not expected because 
patients with MMA who have received replacement liver and kid-
ney combined transplantation procedures also display persistent 
MMA and methylmalonic aciduria.16,17 Also, there is no evidence 
to suggest that free methylmalonic acid can be efficiently metabo-
lized, even when delivered exogenously to a wild-type host.
Consistent  with  many  previous  studies,  the  rAAV8-mMut 
vector produced persistent expression in the liver and muscle 
that was readily detected at 90 days after therapy at the mRNA 
and protein level, and at 1 year through mRNA expression and 
in vivo propionate oxidation. Because the mice were treated at 
the time of birth, the rapid growth of the liver and subsequent 
dilution in the number of transduced cells by cell division likely 
explains the relative diminution of Mut expression over time.32 
The cohort of treated Mut−/− mice, which is >25, have survived 
to 1 year and beyond, demonstrating that even low levels of Mut 
expression are sufficient to provide metabolic homeostasis, and 
prevent morbidity and mortality. Furthermore, although formal 
testing has not been performed, the mutant animals appeared 
clinically well, with no obvious neurological or behavioral phe-
notypes. rAAV-based gene vectors have previously shown prom-
ising  proof-of-principle  correction  in  other  mouse  models  of 
metabolic disease33 and now includes a pleiotropic disorder of 
organic acid metabolism.
The hereditary MMAs, as well as other inborn errors of metab-
olism that lack conventional therapy, are included in routine new-
born screening panels used by many states and countries.34 There 
has been a vigorous and public debate on the inclusion of these 
disorders in the list of conditions for which screening is offered. 
In this report, we have demonstrated that a single injection of 
rAAV8-mMut was sufficient to cure the lethal phenotype of Mut 
deficiency in a murine model of MMA that closely replicates the 
human condition. Our studies are the first to demonstrate that 
MMA, and by extension other organic acidemias, might be treated 
by gene therapy with a safe and effective vector. This conclusion 
offers strong support for the continued and expanded screening of 
infants for disorders of intermediary metabolism and to the appli-
cation of gene therapy to humans with MMA.
MAterIAls And Methods
Murine model of MMA. The targeted Mut allele harbors a deletion of exon 
3 in the Mut gene. This exon encodes the putative substrate-binding pocket 
in the Mut enzyme. The Mut allele does not produce mature RNA, protein, 
or enzymatic activity.20 Mut−/− mice on a mixed (C57BL/6 × 129SV/Ev × 
FvBN) background exhibit a semipenetrant neonatal lethal phenotype with 
most mice perishing in the early neonatal period.21 Coat colors are variable 
in these mice due to parental strain contributions. Mut−/− mice display 
massively elevated methylmalonic acid concentrations in the plasma that 
progressively rises to the 2 mmol/l range until death occurs. Mut+/− ani-
mals have biochemical parameters identical to Mut+/+ wild-type animals 
and were used as controls throughout.
rAAV8  construction,  production,  and  delivery. Th e  U n i v e r s i t y  o f  
Pennsylvania Vector Core provided the expression vector, p-AAV2-CI-
CB7-RBG. The vector contains transcriptional control elements from the 
cytomegalovirus enhancer/chicken β-actin promoter, cloning sites for the 
insertion of a complementary DNA, and the rabbit β-globin polyA signal.35 
Terminal repeats from AAV serotype 2 flank the expression cassette. Either 
the murine Mut (mMut) or GFP was cloned into pAAV2/8.CI.CB7.RBG 
and packaged into rAAV8, purified by cesium chloride centrifugation, and 
titered by qPCR as previously described.26 pAAV2/8.CI.CB7.EGFP.RBG 
had a titer of 2.25 × 1013 GC/ml and pAAV2/8.CI.CB7.mMut.RBG had a 
titer of 4.13 × 1013 GC/ml. Animal studies were reviewed and approved by 
the National Human Genome Research Institute Animal User Committee. 
Hepatic  injections  were  performed  on  nonanesthetized  neonatal  mice, 
typically within several hours after birth. Viral particles were diluted to 
a total volume of 20 microliters with phosphate-buffered saline immedi-
ately before injection and were delivered into the liver parenchyma using a 
32-gauge needle and transdermal approach, as previously described.22
Quantitative real-time PCR. Total RNA was extracted using RNeasy Mini 
Kit (Qiagen, Valencia, CA), and DNase digested was preformed using 
DNA-free (Ambion, Austin, TX). qPCR was accomplished with TaqMan 
gene  expression  assays  [mouse  GAPD  (4352932E)  and  murine  Mut 
(Mm00485312_m1) from Applied Biosystems, Foster City, CA]. Samples 
were analyzed in an Applied Biosystems 7500 fast real-time PCR system, in 
accordance with the manufacturer’s protocol. All samples were analyzed in 
triplicate. Three individual mouse tissue samples were used to determine 
the 100% comparator Mut+/− Mut mRNA expression level.
Western blotting. Tissue samples were homogenized with a 2-ml Tenbroeck 
tissue grinder (Wheaton, Millville, NJ) in T-PER (Pierce Biotechnology, 
Rockford, IL) tissue protein extraction buffer in the presence of Halt (Pierce 
Biotechnology) protease inhibitor cocktail. Twenty micrograms of clarified 
extract were used in western analysis and probed with   affinity-purified, rab-
bit polyclonal antisera raised against the murine Mut enzyme.23 Complex III 
Core II was used as a loading control and was also detected by immunoblot-
ting [mouse monoclonal anti-OxPhos Complex III (ubiquinol-  cytochrome 
c oxidoreductase) Core II antibody, Invitrogen SKU# A-11143]. The anti-
mutase antibody was used at a dilution of 1:750, and the anti-  Complex 
III Core II antibody was used at a dilution of 1:2,000. Horseradish perox-
idase–conjugated anti-rabbit IgG (NA934; GE Healthcare Life Sciences, 
Piscataway, NJ) or rabbit anti-goat IgG (sc-2768; Santa Cruz Biotechnology, 
Santa Cruz, CA) was used as the secondary antibody and was visualized 
with chemiluminescence detection (Pierce Biotechnology).
Metabolic studies. Plasma was isolated from blood collected by orbital 
bleeding. The samples were immediately centrifuged, and the plasma 
was removed, diluted in water, and stored at −80 °C in a screw-top tube 
for later analysis. Methylmalonic acid was analyzed by gas chromatog-
raphy–mass  spectrometry  with  stable  isotopic  internal  calibration  to 
measure methylmalonic acid as previously described.36,37 In vivo 1-13C-
propionate  oxidation  was  determined  by  collecting  expired  gas  from 16  www.moleculartherapy.org  vol. 18 no. 1 jan. 2010     
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mutant, control, and treated mice after the animals were injected by the 
  intraperitoneal route with 200 micrograms of 1-13C-sodium propionate, 
using an adaptation of a method developed to study propionate oxida-
tion in patients with methylmalonic and propionic acidemia.38 The mice 
were placed into a respiratory chamber that contained a CO2 probe to 
allow the direct measurement of CO2 generated by each animal. An ali-
quot of expired air was removed from the chamber at each time point 
for analysis of 13C enrichment in CO2. The isotope ratio (13C/12C) of the 
expired gas was determined with a gas isotope ratio mass spectrometer 
(Metabolic Solutions, Nashua, NH). The percent dose metabolized at 
each time point was calculated as % dose   metabolized = total 13C excreted 
(mmol/dose (mmol) × 100%).
Statistical analyses. In all instances, P values were considered significant 
if the value was <0.05. Differences in the survival between treated groups 
were analyzed using a χ2 test. The weights between treated and untreated 
mice, and differences in metabolite levels were assessed using a two-sided, 
two-tailed unpaired Student’s t- test. The Kruskal–Wallis test was used to 
determine the statistical significance in measured propionate oxidation 
rates between groups.
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